Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4794420
Max Phase: Preclinical
Molecular Formula: C77H120N20O19
Molecular Weight: 1629.93
Molecule Type: Unknown
Associated Items:
ID: ALA4794420
Max Phase: Preclinical
Molecular Formula: C77H120N20O19
Molecular Weight: 1629.93
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)O
Standard InChI: InChI=1S/C77H120N20O19/c1-8-43(6)62(72(112)94-57(75(115)116)38-42(4)5)95-69(109)56(40-46-22-26-48(99)27-23-46)93-71(111)59-19-14-36-97(59)74(114)53(17-12-34-84-77(81)82)90-65(105)49(16-11-33-83-76(79)80)88-70(110)58-18-13-35-96(58)73(113)52(15-9-10-32-78)89-63(103)44(7)85-64(104)51(29-31-61(101)102)87-68(108)55(39-45-20-24-47(98)25-21-45)92-67(107)54(37-41(2)3)91-66(106)50-28-30-60(100)86-50/h20-27,41-44,49-59,62,98-99H,8-19,28-40,78H2,1-7H3,(H,85,104)(H,86,100)(H,87,108)(H,88,110)(H,89,103)(H,90,105)(H,91,106)(H,92,107)(H,93,111)(H,94,112)(H,95,109)(H,101,102)(H,115,116)(H4,79,80,83)(H4,81,82,84)/t43-,44-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-/m0/s1
Standard InChI Key: ACFFVPRDWLCNQO-KNQVYGPCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1629.93 | Molecular Weight (Monoisotopic): 1628.9039 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Chartier M,Desgagné M,Sousbie M,Côté J,Longpré JM,Marsault E,Sarret P. (2021) Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic., 64 (4.0): [PMID:33538583] [10.1021/acs.jmedchem.0c01726] |
Source(1):